Merck and Pfizer’s diabetes therapy under US, EU review

7th March 2017 Uncategorised 0

Regulators on both sides of the Atlantic are reviewing three new submissions for medicines containing ertugliflozin, an investigational SGLT2 inhibitor being developed by Merck and Pfizer to help improve glycaemic control in adults with type II diabetes.

More: Merck and Pfizer’s diabetes therapy under US, EU review
Source: News